A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Advanced Solid Tumor (Phase 1) · Pancreas Adenocarcinoma · Non-small Cell Lung Cancer · Malignant Melanoma (Cutaneous)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Apr 2025, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 1/2
- Patients
- 30 (final count)
- Started
- Feb 27, 2024
- Main results expected
- Apr 30, 2025
- Fully finished
- Apr 30, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1/2a: Adverse Events
Measured over: From treatment initiation through 30 days following the last IMM-6-415 dose
Phase 1: Dose-Limiting Toxicities (DLT)
Measured over: The first 21 days of study treatment
Phase 1: Recommended Phase 2 Dose (RP2D) candidate
Measured over: Initiation of study treatment through 21 days (up to approximately 18 months)
Phase 1: Maximum Observed Plasma Concentration of IMM-6-415
Measured over: After 9 weeks (3 Cycles) of study treatment
Phase 1: Time to Reach Maximum Observed Plasma Concentration of IMM-6-415
Measured over: After 9 weeks (3 Cycles) of study treatment
Phase 1: Area Under Plasma Concentration (AUC) Time Curve of IMM-6-415
Measured over: After 9 weeks (3 Cycles) of study treatment
Phase 1: Pharmacodynamic (PD) Activity of IMM-6-415 Plasma Concentrations Over Time
Measured over: After 9 weeks (3 Cycles) of study treatment
Phase 2a: Overall Response Rate (ORR)
Measured over: After up to 48 weeks (16 cycles) of study treatment
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-04-30, no fading
Raw record changes
- none yet
Trial ID NCT06208124 · record last updated 2025-05-28 · checked 2026-11-09 15:47 UTC